New Brunswick Scientific Expands Exclusive Distribution Agreement With Fisher Scientific to Europe
Thursday October 24, 11:51 am ET
EDISON, N.J., Oct. 24 /PRNewswire-FirstCall/ -- New Brunswick Scientific Co., Inc. (Nasdaq: NBSC - News; "NBS"), today announced that it has entered into a European distributorship agreement with $3-billion global laboratory equipment supplier Fisher Scientific International, Inc.
ADVERTISEMENT
The agreement grants Fisher Scientific exclusive rights to distribute NBS' C-Line laboratory shakers and accessories in Belgium, France, Germany, Poland, Switzerland and The Netherlands for a three-year period, with automatic renewal for successive one-year periods. The agreement excludes sales of the Company's Innova brand shakers, which NBS currently markets directly and through other distribution channels.
New Brunswick Scientific co-founder and Chairman David Freedman commented, "Last year, we announced a three-year contract extension of our exclusive Domestic distribution agreement with Fisher. The successful negotiation of the European distributorship agreement extends our long-standing relationship with this well-known and respected international organization, further strengthening our global presence."
Fisher Scientific International, Inc., is a worldwide source of laboratory supplies and equipment, integrated e-commerce procurement technology and related services for scientific research and analytical testing, healthcare science education and occupational safety. Serving over 350,000 customers and offering more than 600,000 products and services, Fisher posted its 47th consecutive year of increased sales in 2001.
New Brunswick Scientific Co., Inc., designs and manufactures a wide variety of research equipment and scientific instruments for the life sciences and holds a minority equity position in DGI BioTechnologies, Inc., a drug-lead-discovery operation.
This press release includes statements that may constitute forward-looking statements made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. This information may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Further information concerning risk factors is described in the Company's Securities and Exchange Commission filings. |
